非缺血性心肌病患者的一级预防植入式心律转复除颤器:一项Meta分析
该Meta分析检索2000年1月1日至2016年10月31日的PubMed等来源,纳入4项随机临床试验共1874例非缺血性心肌病患者(ICD组937例,对照组937例),评估一级预防ICD与全因死亡率的关系。汇总分析显示ICD显著降低全因死亡率(HR 0.75,95%CI 0.61-0.93,P=.008;异质性P=.87),作者认为该结果支持相关专业指南推荐在此类患者中使用ICD。
要点
- 4项随机临床试验共1874例非缺血性心肌病患者,ICD组与对照组各937例。
- 一级预防ICD显著降低全因死亡率(HR 0.75,95%CI 0.61-0.93,P=.008)。
- 作者认为该结果支持专业指南推荐在此类患者中使用ICD。
核心结论
- 一级预防ICD可有效降低非缺血性心肌病患者的全因死亡率。
- 作者认为这些发现支持专业指南推荐在此类患者中使用ICD。
研究设计与样本
- 研究为Meta分析,检索PubMed自2000年1月1日至2016年10月31日,并补充相关文献参考文献及专家咨询。
- 纳入标准为随机临床试验设计、比较ICD与药物治疗(对照)、至少100例非缺血性心肌病患者、报告至少12个月随访的全因死亡率、以英文发表。
- 共纳入4项随机临床试验,1874例独特患者,ICD组937例,对照组937例。
- 采用PRISMA指南提取数据并评估数据质量与有效性,使用固定效应和随机效应模型汇总数据。
主要发现
- 汇总4项试验显示,ICD组较对照组显著降低全因死亡率(HR 0.75,95%CI 0.61-0.93,P=.008)。
- 异质性检验P=.87。
关键数值与推荐
- 主要终点为全因死亡率。
- 数据收集开始前假设一级预防ICD可降低非缺血性心肌病患者的全因死亡率。
临床怎么用
- 作者认为这些发现支持专业指南推荐在此类患者中使用ICD。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Conflicting data have emerged on the efficacy of implantable cardioverter defibrillators (ICDs) for primary prevention of sudden cardiac death (primary prevention ICDs) in patients with nonischemic cardiomyopathy. OBJECTIVE: To investigate the association of primary prevention ICDs with all-cause mortality in patients with nonischemic cardiomyopathy. DATA SOURCES: PubMed was searched from January 1, 2000, through October 31, 2016, for the terms implantable defibrillator OR implantable cardioverter defibrillator AND non-ischemic cardiomyopathy. Additional references were identified from bibliographies of pertinent articles and queries to experts in this field. STUDY SELECTION: Inclusion criteria consisted of a randomized clinical trial design and comparison of the ICD with medical therapy (control) in at least 100 patients with nonischemic cardiomyopathy. In addition, studies had to report on all-cause mortality during a follow-up period of at least 12 months and be published in English. The search yielded 10 studies, of which only 1 met the inclusion criteria. A search of bibliographies of pertinent articles and queries of experts in this field led to 3 additional studies. DATA EXTRACTION AND SYNTHESIS: The PRISMA guidelines were used to abstract data and assess data quality and validity. Data were pooled using fixed- and random-effects models. MAIN OUTCOMES AND MEASURES: The primary end point was all-cause mortality. Before data collection started, primary prevention ICDs were hypothesized to reduce all-cause mortality among patients with nonischemic cardiomyopathy. RESULTS: Four randomized clinical trials met the selection criteria and included 1874 unique patients; 937 were in the ICD group and 937 in the control group. Pooling data from these trials showed a significant reduction in all-cause mortality with an ICD (hazard ratio, 0.75; 95% CI, 0.61-0.93; P = .008; P = .87 for heterogeneity). CONCLUSIONS AND RELEVANCE: Primary prevention ICDs are efficacious at reducing all-cause mortality among patients with nonischemic cardiomyopathy. These findings support professional guidelines that recommend the use of ICDs in such patients.
引用
- Al-Khatib SM, Fonarow GC, Joglar JA, et al. Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis. JAMA Cardiol. 2017. PMID: 28355432. doi:10.1001/jamacardio.2017.0630
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。